Fulgent Genetics CFO Kim Paul Reduces Stake Through Tax-Related Share Withholding

Overview of the Stock Transaction

Kim Paul, who serves as Chief Financial Officer and Treasurer of Fulgent Genetics, Inc., disclosed a stock transaction executed on July 26, 2026. According to the disclosure filing, Paul disposed of 2,747 shares of Fulgent Genetics common stock through a share withholding arrangement. The transaction was executed at a price of $19.67 per share, generating gross proceeds of approximately $54,010 before any adjustments.

The sale reduced Paul's direct beneficial ownership in Fulgent Genetics to 359,798 shares following the completion of the transaction. This transaction represents a routine administrative action tied to tax obligations rather than a voluntary market sale initiated by the executive officer.

Tax Withholding Origins and Merger Background

The disclosure filing explains that the share withholding was necessary to satisfy tax obligations that arose upon the vesting of certain restricted stock units. These units were assumed by Paul pursuant to the Agreement and Plan of Merger dated November 7, 2022, which involved Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed in that agreement. The original awards tied to these restricted stock units were previously reported on a Form 4 filing submitted to the Securities and Exchange Commission on November 9, 2022.

Under standard tax treatment, when restricted stock units vest, employees and executives typically face immediate tax liabilities. Companies frequently permit employees to satisfy these tax withholding obligations through the automatic withholding of shares otherwise due upon vesting. This mechanism prevents executives from needing to generate cash through open-market sales or other means to cover tax bills.

Kim Paul's Role at Fulgent Genetics

Kim Paul holds the position of Chief Financial Officer and Treasurer at Fulgent Genetics, Inc., making him a Section 16 reporting person under Securities Exchange Act regulations. Officers in senior financial positions are required to report changes in beneficial ownership of company equity to the Securities and Exchange Commission, regardless of whether transactions are voluntary market sales or routine administrative actions such as tax withholding.

As CFO and Treasurer, Paul is responsible for the company's financial management, accounting functions, and treasury operations. His disclosure of this transaction reflects the regulatory obligation that all company insiders, including executive officers, must maintain transparency regarding their equity interests in the issuer.

Beneficial Ownership Status Following Transaction

Following the July 26, 2026 transaction, Kim Paul beneficially owns 359,798 shares of Fulgent Genetics common stock on a direct basis. The filing indicates that all of Paul's beneficial ownership is held directly, with no indirect ownership through trusts, family partnerships, or other arrangements disclosed in this transaction report.

Beneficial ownership calculations include all shares over which an individual exercises sole or shared voting or investment power, including restricted stock units that have vested or are otherwise subject to ownership. The disclosure of the post-transaction beneficial ownership figure provides investors with a clear picture of Paul's equity stake in the company following the share withholding event.

Transaction Mechanics and Withholding Authority

The share withholding mechanism used in this transaction represents one of the standard methods through which publicly held companies manage the tax withholding obligations that arise when equity awards vest. Rather than requiring executives to sell shares on the open market or remit cash to cover withholding taxes, the company withholds a number of shares equal to the employee's estimated tax liability and sells those shares on behalf of the executive.

This approach serves multiple purposes: it ensures that tax withholding obligations are met promptly, reduces administrative burden on executives, and can be structured to comply with insider trading policies and blackout period restrictions. The specific authorization for share withholding in connection with tax obligations on equity awards is typically included in award agreements and company equity plan documents.

Regulatory Disclosure Requirements

Section 16 of the Securities Exchange Act of 1934 requires officers, directors, and ten percent beneficial owners of public companies to report transactions in company securities. Kim Paul's status as Chief Financial Officer triggered this reporting obligation, requiring disclosure on Form 4 within two business days of the transaction date. The filing was submitted on July 28, 2026, two business days after the July 26 transaction date.

Form 4 filings provide detailed information about the transaction, including the security, transaction date, transaction code, number of shares involved, price paid or received, and resulting beneficial ownership. These disclosures are intended to provide investors and the broader market with transparency regarding insider transactions and changes in insider holdings.

Share Price Context

The shares were withheld and disposed of at a price of $19.67 per share. The immediate share price impact was not clear from available public information. Investors analyzing insider transactions typically compare the transaction price to surrounding trading prices and broader market conditions to assess the timing and context of insider trading activities.

Since this transaction was executed through mandatory tax withholding rather than a discretionary sale decision by the executive, the transaction price reflects the market price on the withholding date rather than a pricing decision made by Paul. This distinction is relevant when analysts evaluate insider transaction patterns and potential signal value to other investors.

Historical Context of the Merger Award

The restricted stock units that vested to trigger this tax withholding originated from the November 2022 merger involving Fulgent Genetics and Fulgent Pharma Holdings. In merger transactions, acquirers frequently assume, convert, or replace equity awards held by employees and executives of the acquired company. The vesting schedule of assumed awards typically continues according to the original terms, or may be accelerated or modified based on merger agreement provisions.

The fact that restricted stock units are still vesting in July 2026, nearly four years after the November 2022 merger signing, suggests that these awards had a multi-year vesting schedule or that vesting was structured to extend over several years post-closing. The disclosure provides continuity in tracking the ultimate impact of the merger transaction on insider holdings and compensation.

Implications for Investor Monitoring

Investors monitoring insider transactions at Fulgent Genetics may track Form 4 filings to understand patterns of insider buying or selling, changes in insider confidence in the company's direction, and the overall alignment of insider interests with those of public shareholders. Tax-driven withholding transactions, as in this case, typically carry less analytical weight than voluntary open-market sales or purchases made at the discretion of insiders.

The continued presence of these vesting awards and resulting tax withholding events indicates that the company's compensation structure includes equity components that extend well beyond the initial merger date. Investors interested in executive compensation trends and insider ownership may wish to monitor future Form 4 filings for additional information about vesting schedules and any changes in Kim Paul's beneficial ownership position.